India Globalization Capital, Inc. (NYSE: IGC) – Blockbuster Position for Treating Alzheimer’s
IGC purchased exclusive rights to USF patent focused on preventing amyloid-beta plaques from aggregating on neurons Company plans to pursue clinical trials related to this patent on path to FDA approval In 2017, direct costs associated with Alzheimer's and other dementias will total an estimated $259 billion, according to the Alzheimer's Association If you are an investor, there have been significant developments over the past year that you should be tracking. These include remarkable, if preliminary, results regarding the effect of THC on amyloid-beta plaques, the plaques on neurons associated with Alzheimer’s disease, as well as a critical link between…